Trial · NCT06536413
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
NCT06536413, Phase 1, Phase 2, Recruiting, The Methodist Hospital Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ATRA and Carfilzomib in Plasma Cell Myeloma Patients. Trials, record NCT06536413. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06536413
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ATRA and Carfilzomib in Plasma Cell Myeloma Patients
- NCT number
- NCT06536413
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 42 participants, estimated
- Lead sponsor
- The Methodist Hospital Research Institute
- Conditions
- Multiple Myeloma
- Interventions
- All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose -1, All-Trans Retinoic Acid (ATRA) Dose 1
- First posted
- 2024-08-05
- Last updated
- 2026-04-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of ATRA in combination with Carfilzomib/ Dexamethazone and RP2D | From date of initial treatment until progression, unacceptable toxicity, treating physician's discretion, or patient withdraws from the study, whichever came first, assessed up to 7 months. | To determine safety and tolerability of ATRA in combination with carfilzomib/dexamethasone and determine the recommended phase II dose (RP2D). The RP2D will be defined as the highest dose administered at which 6 patients are treated with with no more than 2 experiencing dose limiting toxicity (DLT) (determined by diseases progression, unacceptable toxicity, physician's discretion). |
| Secondary | Efficacy of combination therapy of ATRA, Carfilzomib, and Dexamethasone in resistant Multiple Myeloma | From date of initial treatment until progression, unacceptable toxicity, treating physician's discretion, or patient withdraws, whichever came first, assessed up to 7 months. | Overall Response Rate (percentage of patients with complete response \[CR\] or partial response \[PR\]), as defined by International Myeloma Working Group (IMWG) criteria. |
| Secondary | Duration of Response of combination therapy of ATRA, Carfilzomib, and Dexamethasone in resistant Multiple Myeloma | From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease, whichever came first, assessed up to 7 months after initial treatment date. | Duration of response rate as defined by the duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease. |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | The dose limiting toxicity period begins from date of initial treatment until 21 days after. | Toxicity and safety, as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. |
| Secondary | Disease response as measured by serum, viable cryopreserved peripheral blood mononuclear cells, and bone marrow myeloma plasma cells. | Correlative samples will be collected at Baseline, Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1. Cycles are 28 days in length. | To characterize the disease response of the ATRA and carfilzomib/dexamethasone combination as measured by serum, viable cryopreserved peripheral blood mononuclear cells, and bone marrow myeloma plasma cells. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers44
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06536413
GET https://conductscience.org/api/trials/v1/NCT06536413/papers?page=2